More Than 40,000 Patients Treated with CyberKnife Radiosurgery Worldwide
SUNNYVALE, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that its CyberKnife(R) Robotic Radiosurgery System has been used to treat more than 4,000 lung cancer patients worldwide. The company also reported that more than 40,000 patients in total have been treated with CyberKnife radiosurgery for tumors throughout the body.
In April 2007, Accuray announced that the number of lung tumor patients treated with the CyberKnife System had surpassed 2,000. In the span of seven months, that number doubled, demonstrating the growing clinical adoption of this treatment modality in lung cancer care.
This significant growth is due in part to the increasing availability of Accuray's unparalleled lung cancer treatment offerings at CyberKnife centers. These one-of-a-kind offerings include the Synchrony(R) Respiratory Tracking System, which continuously synchronizes radiation beam delivery with the motion of the tumor, and the Xsight(R) Lung Tracking System, which uses the body's internal anatomy to precisely track lung tumors non-invasively. It is expected that this number will continue to increase significantly with the launch of M. D. Anderson's prospective clinical lung study, which Accuray announced last month.
According to the American Cancer Society (ACS), lung cancer is the leading cause of cancer-related deaths in the United States and will account for approximately 29 percent of all cancer deaths in 2007. The ACS projects that more than 213,000 new cases of lung cancer will be discovered this year, accounting for 15 percent of all cancer diagnoses.
"In cancer care, the paradigm is shifting toward less invasive treatment alternatives that exhibit fewer risks, fewer side effects and decreased recovery times," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The rapid increase in lung cancer patients treated with our System proves that this is a reality. More and more patients are opting for CyberKnife radiosurgery as a non-invasive means of treating their cancer and maintaining their quality of life."
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-Q for the quarterly period ended September 29, 2007 and may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward- looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
|SOURCE Accuray Incorporated|
Copyright©2007 PR Newswire.
All rights reserved